Evidence map›Paper›PMID 42199152›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Canagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota-Dependent Manner.

Wei Zhang, Yi Song, Changkun Li, Yuanyuan Luo, Mingwei Shao, Feng Guo, Fangyi Wei, Xunjie Fan, Wenwen Guo, Fengmei Xu and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Wei ZhangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID https://orcid.org/0000-0001-5972-6744
Yi SongDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Changkun LiDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuanyuan LuoDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Mingwei ShaoDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Feng GuoDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Fangyi WeiDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xunjie FanDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wenwen GuoDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Fengmei XuDepartment of Endocrinology and Metabolism, Hebi Coal Industry (Group) Co., Ltd, General Hospital, Hebi, China.
Yanhong SangDepartment of Endocrinology and Metabolism, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Dongming ZhangDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yanhong ZhouDepartment of Endocrinology, Xinxiang Central Hospital, Xinxiang, China.
Lianwei WangDepartment of Endocrinology, Zhumadian Central Hospital, Zhumadian, China.
Zhiqiang KangDepartment of Endocrinology and Metabolism, Zhengzhou Central Hospital, Zhengzhou, China.
Yingjun YangDepartment of Endocrinology and Geriatrics, The Seventh People's Hospital of Zhengzhou, Zhengzhou, China.
Chunhua SongDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, China.
Yanxia LiuDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiaojun MaDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jiao WangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Chong LiDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shengnan MaDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lin ZhaoDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhi QinDepartment of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Guolan XingDepartment of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qiubo ZhaoDepartment of Endocrinology and Metabolism, Hebi Coal Industry (Group) Co., Ltd, General Hospital, Hebi, China.
Jun LiDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shumin SongDepartment of Endocrinology and Metabolism, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Dan ZhaoDepartment of Endocrinology, Zhumadian Central Hospital, Zhumadian, China.
Ting HuangDepartment of Endocrinology and Geriatrics, The Seventh People's Hospital of Zhengzhou, Zhengzhou, China.
Qingzhu WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yanyan ZhaoDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Guijun QinDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID https://orcid.org/0000-0002-2503-7534

Funding

Henan Joint Construction Program LHGJ20230200Key Research and Development Program of Henan Province 251111311500National Natural Science Foundation of China 82170839National Natural Science Foundation of China 82300930National Natural Science Foundation of China 82470876National Natural Science Foundation of China U23A20414Natural Science Foundation of Henan Province 242300421272Science and Technology Research Project of Henan Province SBGJ202301006
6 · The paper itself

Abstract

Canagliflozin reduces albuminuria in patients with diabetic kidney disease (DKD) beyond its glucose-lowering effect, but the mechanisms remain unclear. We analyzed 85 patients treated with canagliflozin and 85 controls over 26 weeks to explore whether the gut microbiome and its metabolites contribute to renoprotection. Canagliflozin remodeled the gut microbiota, notably enriching Roseburia intestinalis and increasing plasma melibiose levels. In mice, canagliflozin alleviated glomerular endothelial injury and albuminuria. Similar effects were replicated by fecal microbiota transplantation, Roseburia intestinalis, or melibiose administration. Mechanistically, melibiose bound to and activated glyoxalase 1, reduced methylglyoxal, and suppressed the AGE-RAGE pathway, preserving glomerular endothelial integrity. Furthermore, oral melibiose precursor supplementation reduced albuminuria in patients with early-stage DKD. These findings suggest the involvement of a gut-kidney axis in the renoprotective effects of canagliflozin and indicate that melibiose may serve as a potential therapeutic strategy for DKD.

Indexed as

canagliflozindiabetic kidney diseaseglomerular endothelial injuryglyoxalase 1gut‐kidney axismelibiose

Identifiers

PMID42199152
PMCPMC13335814

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.